Accession Number:

ADA218343

Title:

The Development of a Micro Assay for Natural Killer and Lymphokine-Activated Killer Activity and Its Use in Monitoring the Purification of an Interleukin-2 Inhibitor

Descriptive Note:

Master's thesis

Corporate Author:

AIR FORCE INST OF TECH WRIGHT-PATTERSON AFB OH

Personal Author(s):

Report Date:

1989-05-01

Pagination or Media Count:

102.0

Abstract:

The treatment of cancer is a constantly changing field and has recently expanded to include immunotherapy. One of the recent advances in cancer immunotherapy involves the infusion of lymphokine-activated killer LAK cells. The LAK cells are derived from the patients own lymphocytes which are incubated with interleukin-2 IL-2 for a few days. The IL-2 augments the cytotoxicity of a subpopulation of these lymphocytes, increasing their ability to kill tumor cells. As an adjunct to the LAK cells, interleukin-2 IL-2 is often administered intravenously to maintain the LAK cells enhanced cytotoxicity. Unfortunately, the high doses of IL-2 required for this LAK maintenance are often toxic to the patient. The purpose of this research was to partially purify the IL-2 inhibitor from normal mouse serum. The partially purified IL-2 inhibitor was used to induce antibody formation. The polyclonal antiserum was tested for its neutralizing capability and will be used to further purify and characterize the inhibitor. Keywords Chemotherapy Cancer.

Subject Categories:

  • Medicine and Medical Research
  • Pharmacology

Distribution Statement:

APPROVED FOR PUBLIC RELEASE